Elite in Peripheral T-Cell Lymphoma

Dr. Barbara Pro

Oncology
Trustees Of Columbia University In The City Of New York
622 W 168th St, 
New York, NY 
Offers Telehealth
32 Years of Experience
Elite in Peripheral T-Cell Lymphoma
Trustees Of Columbia University In The City Of New York
622 W 168th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Barbara Pro is an Oncologist in New York, New York. Dr. Pro has been practicing medicine for over 32 years and is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 133 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 35 articles and participated in 4 clinical trials in the study of Peripheral T-Cell Lymphoma.

Specialties
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MVP Health
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: Duvelisib
Study Phase: Phase 2
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2024
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Lenalidomide
Study Phase: Phase 2
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2024
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)
Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)
Enrollment Status: Withdrawn
Publish Date: October 10, 2023
Intervention Type: Drug, Biological
Study Drugs: Brentuximab Vedotin, Pembrolizumab
Study Phase: Phase 2
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: June 02, 2023
Intervention Type: Procedure, Drug, Radiation, Other, Biological
Study Drugs: Dacarbazine, Doxorubicin, Pembrolizumab, Vinblastine, 18F-Fludeoxyglucose
Study Phase: Phase 2
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
Enrollment Status: Unknown
Publish Date: June 02, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Carboplatin, Etoposide, Ifosfamide, Pembrolizumab
Study Phase: Phase 2
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen
Enrollment Status: Unknown
Publish Date: February 21, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate
Study Phase: Phase 1/Phase 2
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Enrollment Status: Completed
Publish Date: July 08, 2019
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 10 Less Clinical Trials

133 Total Publications

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.
Journal: Leukemia & lymphoma
Published: August 14, 2025
Similar Doctors
Elite in Peripheral T-Cell Lymphoma
Dr. Steven M. Horwitz
Oncology
Elite in Peripheral T-Cell Lymphoma
Dr. Steven M. Horwitz
Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (5.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Horwitz is an Oncologist in New York, New York. Dr. Horwitz is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration.

Elite in Peripheral T-Cell Lymphoma
Dr. Owen A. O'connor
Oncology
Elite in Peripheral T-Cell Lymphoma
Dr. Owen A. O'connor
Oncology
41 E Post Rd, 
White Plains, NY 
 (15.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Owen O'connor is an Oncologist in White Plains, New York. Dr. O'connor is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Anaplastic Large Cell Lymphoma.

Francine M. Foss
Elite in Peripheral T-Cell Lymphoma
Dr. Francine M. Foss
Oncology
Elite in Peripheral T-Cell Lymphoma
Dr. Francine M. Foss
Oncology

Yale University

20 York St, 
New Haven, CT 
 (61.4 miles away)
203-688-2433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francine Foss is an Oncologist in New Haven, Connecticut. Dr. Foss is rated as an Elite provider by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Non-Hodgkin Lymphoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pro's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 7 Advanced Conditions
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile